ArticlePharmacoEconomics - open2025

A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra).

Rajiv Mallick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.